Mechanisms of Disease: Angiogenesis and the Management of Breast Cancer

Overview

Journal Nat Clin Pract Oncol

Specialty Oncology

Date 2007 Aug 31

PMID 17728712

Citations 61

Authors

Susana Banerjee

Mitch Dowsett

Alan Ashworth

Lesley-Ann Martin

Affiliations

Soon will be listed here.

Abstract

Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.

Citing Articles

Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform.

Jung S, Cheong S, Lee Y, Lee J, Lee J, Kwon M ACS Nano. 2024; 18(36):24909-24928.

PMID: 39208278 PMC: 11394367. DOI: 10.1021/acsnano.4c05537.

The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.

Huang J, Chen X, Xie X, Song L, Chen L, Lan X Cancer Med. 2024; 13(8):e7181.

PMID: 38659376 PMC: 11043681. DOI: 10.1002/cam4.7181.

[Adequacy of histopathology request forms and pathological reports of breast cancer surgical specimens in Benin].

Gnangnon F, Seidou F, Laleye C, Odidi F, Flenon Nakou A, Tonato Bagnan J Med Trop Sante Int. 2024; 3(4).

PMID: 38390014 PMC: 10879892. DOI: 10.48327/mtsi.v3i4.2023.348.

Using a combination of superb microvascular imaging and other auxiliary ultrasound techniques to increase the accuracy of gray-scale ultrasound for breast masses.

Abedi M, Sahebi L, Eslami B, Saberi A, Orouji M, Alipour S BMC Cancer. 2024; 24(1):224.

PMID: 38365653 PMC: 10873956. DOI: 10.1186/s12885-024-11981-9.

MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B.

Jonas K, Prinz F, Ferracin M, Krajina K, Deutsch A, Madl T Noncoding RNA. 2024; 10(1).

PMID: 38250802 PMC: 10801495. DOI: 10.3390/ncrna10010002.